1 | 20 mg | - | - | - | - | 1件: 97 97 |
2 | 20 mg BID of PF-02545920 | - | - | - | - | 1件: 8 8 |
3 | 20 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
4 | 20 mg GA | - | - | - | - | 1件: 13 13 |
5 | 20 mg MitoQ | - | - | - | - | 1件: 13 13 |
6 | 20 mg sildenafil citrate by mouth | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
7 | 20 mg/ml Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
8 | ACOMPLIA 20 mg film-coated tablets | 1件: Rimonabant Rimonabant | 1件: D05731
D05731
| 1件: CNR1 CNR1 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 193 193 |
9 | ADCIRCA 20 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
10 | Apremilast 20 mg | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 3件: 46 46, 56, 107 |
11 | Apremilast tablet 20 mg | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 271 271 |
12 | Arava 20 mg filmdrasjerte tabletter | - | - | - | - | 1件: 46 46 |
13 | Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.) | 1件: Leflunomide Leflunomide | 1件: D00749
D00749
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 46 46 |
14 | ARC1905 20 MG/ML | - | - | - | - | 1件: 301 301 |
15 | ARZERRA - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 50 ML (20 MG/ML) 1 FLACONCINO + 2 KIT DI PROLUNGA | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
16 | Atorvastatin tablet 20 mg | 1件: Atorvastatin Atorvastatin | 1件: D07474
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 46 46 |
17 | Avatrombopag 20 MG | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 60 60 |
18 | Avatrombopag 20 MG Oral Tablet | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 60 60 |
19 | AZD9567 20 mg | - | - | - | - | 1件: 46 46 |
20 | Baclofen 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
21 | Baclofen ER Capsules (GRS) 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
22 | Bardoxolone methyl 20 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 1件: 67 67 |
23 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 2件: Bezafibrate Bezafibrate, Ursodeoxycholic acid | 2件: D00734
D00734
,
D01366
| 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 |
24 | BF 2.649 20 mg | - | - | - | - | 1件: 6 6 |
25 | BIBR 796 BS, 20 mg | - | - | - | - | 1件: 96 96 |
26 | BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product | - | - | - | - | 1件: 94 94 |
27 | Carbidopa 20 mg | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
28 | Chronocort® 20 mg | - | - | - | - | 1件: 81 81 |
29 | CIALIS - 20 MG 2 COMPRESSE RIVESTITE CON FILM IN BLISTER USO ORALE | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 75 75 |
30 | CIALIS 20 mg comprimidos recubiertos con película | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
31 | Cialis 20 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 |
32 | CK-3773274 (5 - 20 mg) | - | - | - | - | 1件: 58 58 |
33 | CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg) | - | - | - | - | 1件: 58 58 |
34 | COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE 28 SIRINGHE PRERIEMPITE | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 |
35 | COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE 30 SIRINGHE | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 |
36 | Copaxone 20 mg | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 |
37 | Copaxone 20 mg/ml | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 |
38 | COPAXONE 20 mg/ml solución inyectable en jeringa precargada | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 |
39 | Copaxone 20 mg/ml solución para inyección en jeringa precargada | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 |
40 | Copaxone 20 mg/ml Solution for Injection, pre-filled syringe | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 |
41 | Copaxone 20 mg/ml, Solution for Injection, pre-filled syringes | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 |
42 | CORTANCYL 20 mg | 1件: Prednisone acetate Prednisone acetate | 1件: D08416
D08416
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 |
43 | Cortancyl ® 20 mg | 1件: Prednisone acetate Prednisone acetate | 1件: D08416
D08416
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 |
44 | Decortin 20 mg | - | - | - | - | 1件: 96 96 |
45 | Dexamethasone Oral, 20 mg | 1件: Dexamethasone Dexamethasone | 1件: D00292
D00292
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 |
46 | Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg | 3件: Dextromethorphan Dextromethorphan, Quinidine, Sulfate ion | 2件: D03742
D03742
,
D08458
| 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 2件: 2 2, 13 |
47 | Doptelet 20 mg film-coated tablets | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
48 | Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
49 | Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
50 | Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml | - | - | - | - | 1件: 96 96 |
51 | Efgartigimod concentrate for solution for infusion 20 mg/mL | - | - | - | - | 1件: 11 11 |
52 | Encapsulated Baclofen 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
53 | Esomeprazole 20 mg | 1件: Esomeprazole Esomeprazole | 1件: D07917
D07917
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 46 46 |
54 | Famotidine 20 MG | 1件: Famotidine Famotidine (Synonym: Riva-famotidine 20 mg) | 1件: D00318
D00318
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 1件: 86 86 |
55 | GA 20 mg/mL | - | - | - | - | 1件: 13 13 |
56 | Glatiramer acetate 20 mg | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 |
57 | Glatiramer acetate 20 mg, with mitoxantrone | 3件: Acetate Acetate, Glatiramer, Mitoxantrone | 1件: D08224
D08224
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
58 | Glatiramer Acetate 20 mg/0.5 mL | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 |
59 | GWP42003-P 20 mg/kg/day Dose | - | - | - | - | 2件: 140 140, 144 |
60 | Humira 20 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
61 | Humira 20 mg solution for injection in pre-filled syringe (20 mg/0.2mL) | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
62 | Infliximab 20 mg/kg | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
63 | IPX056 20 mg | - | - | - | - | 1件: 13 13 |
64 | IPX056-20 mg | - | - | - | - | 1件: 13 13 |
65 | Isosorbide Dinitrate 20 mg | 1件: Isosorbide dinitrate Isosorbide dinitrate | 1件: D00516
D00516
| - | - | 1件: 113 113 |
66 | Istradefylline 20 mg | 1件: Istradefylline Istradefylline | 1件: D04641
D04641
| 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 |
67 | Istradefylline 20 mg or 40 mg | 1件: Istradefylline Istradefylline | 1件: D04641
D04641
| 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 |
68 | Kesimpta 20 mg Injektionslösung im Fertigpen | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
69 | Kesimpta 20 mg solution for injection in pre-filled pen | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
70 | LCI699, 20 mg | - | - | - | - | 1件: 75 75 |
71 | Leflunomide 20 mg Tablets (Geneva Pharmaceutical) | 1件: Leflunomide Leflunomide | 1件: D00749
D00749
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 46 46 |
72 | Leflunomide 20 mg+prednisone 0.5mg/kg/d | 2件: Leflunomide Leflunomide, Prednisone | 2件: D00473
D00473
,
D00749
| 2件: DHODH DHODH, NR3C1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism 💬 | 1件: 66 66 |
73 | Lenabasum 20 mg | - | - | - | - | 2件: 51 51, 299 |
74 | Lenabasum 20 mg Powder in Capsule | - | - | - | - | 1件: 51 51 |
75 | Lojuxta 20 mg hard capsules | 1件: Lomitapide Lomitapide | 1件: D09637
D09637
| 1件: MTTP MTTP 💬 | 1件: Fat digestion and absorption Fat digestion and absorption 💬 | 1件: 79 79 |
76 | Losec Capsules 20 mg | 1件: Omeprazole Omeprazole (Synonym: Omeprazole 20 mg) | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 46 46 |
77 | LY3337641 20 mg | - | - | - | - | 1件: 46 46 |
78 | MBS2320 20 mg | - | - | - | - | 1件: 46 46 |
79 | Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d | 2件: Melarsoprol Melarsoprol, Nifurtimox | 2件: D00832
D00832
,
D00833
| - | - | 1件: 65 65 |
80 | METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 96 96 |
81 | Methylphenidate modified release 20 mg | 1件: Methylphenidate Methylphenidate | 1件: D04999
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
82 | MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - F | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 19 19 |
83 | MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 |
84 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: D00833
D00833
,
D07883
| 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 |
85 | Omaveloxolone Capsules, 20 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
86 | OsrhAAT 20 mg/kg IV | - | - | - | - | 1件: 231 231 |
87 | OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 |
88 | OXN 20 mg / 10 mg PR | - | - | - | - | 1件: 6 6 |
89 | Oxycodone/naloxone prolonged release tablets 20 mg /10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
90 | Pantoprazolo 20 mg gastro-resistant tablets | - | - | - | - | 1件: 65 65 |
91 | Paroxetine hydrochloride 10 & 20 mg and Prednisolone 1 mg BP | 2件: Paroxetine Paroxetine, Prednisolone | 2件: D00472
D00472
,
D02362
| 2件: NR3C1 NR3C1, SLC6A4 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 |
92 | Paroxetine Hydrochloride tablets 10 & 20 mg and Prednisolone 1 mg BP | 2件: Paroxetine Paroxetine, Prednisolone | 2件: D00472
D00472
,
D02362
| 2件: NR3C1 NR3C1, SLC6A4 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 |
93 | PF-06650833 20 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 |
94 | Plenadren 20 mg modified-release tablets | 2件: Hydrocortisone Hydrocortisone, Manganese citrate | 1件: D00088
D00088
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 |
95 | Plovamer acetate 20 mg | 1件: Acetate Acetate | - | - | - | 1件: 13 13 |
96 | PN 200 tablets (500 mg naproxen and 20 mg omeprazole) | 2件: Naproxen Naproxen, Omeprazole (Synonym: Omeprazole 20 mg) | 2件: D00118
D00118
,
D00455
| 4件: ATP4A ATP4A, ATP4B, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 2件: 46 46, 271 |
97 | Ponesimod 20 mg | 1件: Ponesimod Ponesimod | 1件: D11215
D11215
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
98 | Prednisolon 20 mg JENAPHARM | - | - | - | - | 1件: 41 41 |
99 | Prednisolone 20 mg | 1件: Prednisolone Prednisolone | 1件: D00472
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 |
100 | Prednison acis® 20 mg | - | - | - | - | 2件: 43 43, 44 |
101 | Prednison acis¿ 20 mg | - | - | - | - | 2件: 43 43, 44 |
102 | PTC518 tablet 20 mg | - | - | - | - | 1件: 8 8 |
103 | Revatio 20 mg | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 85 85 |
104 | Revatio 20 mg film coated tablets | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
105 | Revatio 20 mg film-coated tablets | - | - | - | - | 1件: 86 86 |
106 | Revatio 20 mg Filmtabletten | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
107 | REVATIO 20 mg, comprimidos recubiertos con película | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
108 | Revatio ® 20 mg film-coated tablets | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
109 | Rivaroxaban 20 mg | 1件: Rivaroxaban Rivaroxaban | 1件: D07086
D07086
| 1件: F10 F10 💬 | 1件: Complement and coagulation cascades Complement and coagulation cascades 💬 | 1件: 91 91 |
110 | ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
111 | RoActemra 20 mg/ml concentrado para solución para perfusión | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
112 | RoActemra 20 mg/ml Concentrate for solution for infusion | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
113 | RoActemra 20 mg/ml concentrate for solution for infusion. | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
114 | ROACTEMRA 20 mg/ml, concentrado para solución para perfusión | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 46 46, 107, 271 |
115 | Sandostatin LAR 20 mg | 1件: Octreotide Octreotide | 1件: D00442
D00442
| 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 |
116 | SANDOSTATINA - LAR 20 MG/2.5 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE FLACONE POLVERE + SIRINGA PRERIEMPITA 2.5 ML + 2 AGHI | - | - | - | - | 1件: 67 67 |
117 | Sildenafil (Revatio) 20 mg TID | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
118 | Sildenafil 20 mg tablets | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 278 278 |
119 | Simvastatin 20 mg | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 46 46 |
120 | SOM230 LAR, 20 mg | - | - | - | - | 1件: 75 75 |
121 | Tadalafil 20 MG | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 113 113 |
122 | Tadalafil 20 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
123 | Tafamidis meglumine 20 mg soft gelatin capsules | 3件: Gelatin Gelatin, Meglumine, Tafamidis | 4件: D00115
D00115
,
D01796
,
D06892
,
D09673
| 1件: TTR TTR 💬 | 1件: Thyroid hormone synthesis Thyroid hormone synthesis 💬 | 1件: 28 28 |
124 | Targinact 20 mg/10 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 6 6 |
125 | TPI-287 20 mg/m2 | 1件: TPI-287 TPI-287 | - | - | - | 2件: 5 5, 7 |
126 | Triamcinolone Hexacetonide 20 MG/ML | 1件: Triamcinolone Triamcinolone | 1件: D00385
D00385
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 107 107 |